The U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices Advisory Panel today voted that biventricular (BiV) pacing with Medtronic, Inc. (NYSE: MDT) devices is beneficial for treating patients who have atrioventricular (AV) block...
An independent and first-of-its-kind study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, shows there are significant differences in battery longevity between contemporary cardiac resynchronization...
Medtronic has had a lot of action in the courts today, with the Supreme Court sending a negligence lawsuit against the company up to the federal government for a 2nd opinion. The Justices asked the White House to weigh in on a lawsuit that questions preemption laws for medical devices...
Medtronic Diabetes tells Evidenced-Based Diabetes Management that it has applied to CMS for a new code that would cover sensor-augmented insulin pumps, which would broaden Medicare coverage for the new “artificial pancreas” system it unveiled on Friday.
Drug delivery coatings are not a new technology to the medical device industry. However, as more implantable devices are tasked with achieving a greater level of healthcare, they do offer great benefit to design engineers. This article reviews drug coating technology and looks at application areas where it has made a significant impact.
Medtronic Gains Approval of First Artificial Pancreas Device System with Threshold Suspend AutomationSeptember 27, 2013 10:19 am | by Medtronic | News | Comments
Medtronic, Inc. has announced the FDA approval of the MiniMed 530G with Enlite, a breakthrough, first-generation artificial pancreas system with Threshold Suspend automation for people with diabetes. Medtronic’s system is the first in the United States that can automatically stop insulin delivery when sensor glucose values reach a preset level...
A California state court ruled out a series of motions seeking to dismiss a lawsuit filed over bone proteins made by Stryker and Medtronic, ruling that federal law does not preempt the case from going forward. April Cabana sued the medical device companies for alleged off-label promotion of the bone growth products...
FDA Approves Medtronic's Complete 'SE' Vascular Stent for Use in Superficial Femoral and Proximal Popliteal (Leg) ArteriesSeptember 24, 2013 11:42 am | by The Associated Press | News | Comments
Expanding its role in the treatment of peripheral artery disease in the United States, Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the Complete SE (self-expanding) vascular stent for use in the lower extremities -- specifically, the superficial femoral artery (SFA) and proximal popliteal artery (PPA), which carry blood through the upper legs.
Minnesota medical device company Medtronic is closing the books on a years-old wage discrimination case, paying $290,000 to settle claims that it paid Hispanic workers less than white workers. Filed by the U.S. Dept. of Labor, the lawsuit claimed that Medtronic shortchanged 78 Hispanic entry-level employees at a Danvers, Mass., facility.
Medtronic, Inc. has announced clinical trial results showing that heart failure patients treated with its exclusive AdaptivCRT feature experienced a nearly 50 percent reduction in atrial fibrillation (AF) risk. Pioneered by Medtronic, the AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillators...
Medical device titans Medtronic and Boston Scientific cut the ribbon on new facilities overseas this week, looking to develop new technologies that cater to markets in Ireland and China. Minnesota-based Medtronic announced a new $10-million-dollar "brainstorming" center at its Galway, Ireland campus...
A federal appeals court upheld a lower court's decision to toss a lawsuit filed in 2010 accusing Medtronic of violating patents held by W.L. Gore & Associates covering stent graft manufacturing techniques. Judge Mark Davis of the U.S. District Court for Eastern Virginia dismissed Gore's claims last year, saying the ruling made Medtronic's counterclaims moot.
El Camino Hospital Enrolls Second Patient in Global Clinical Trial Evaluating the Medtronic CoreValve® System in Intermediate Risk Patients with Aortic Valve DiseaseSeptember 11, 2013 3:38 pm | by Business Wire | News | Comments
El Camino Hospital, in partnership with the Taft Center for Clinical Research and the Fogarty Clinical Research Institute, both a part of the Fogarty Institute for Innovation, announced today that it has enrolled its second patient in a global clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve replacement in patients with severe aortic stenosis who are at intermediate risk for open-heart surgery.
Medtronic is working with New England hospitals and government health officials to track the movement of surgical medical equipment involved in several cases of possible patient exposure to Creutzfeldt-Jakob disease, a rare and fatal relative to the more commonly known "mad cow" disease.
Medtech titan Medtronic opened the doors on a new Center of Excellence in Singapore, where new business models will be designed, tested and scaled for Asian markets. Based in Medtronic's existing Singapore facility, the new center will also develop commercial models that may eventually extend to various markets around the globe after passing muster in a single country.
New data on Medtronic's Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week. A pair of analyses released during the the European Society of Cardiology Congress in Amsterdam this week showed positive results for the hypertension treatment system.
Medtronic Announces Formation of Hospital Solutions Business Aimed at Driving Efficiencies and Cost SavingsSeptember 2, 2013 12:06 pm | by The Associated Press | News | Comments
Medtronic, Inc. (NYSE: MDT) today announced the formation of Medtronic Hospital Solutions, a new business focused on developing novel partnerships with hospitals to provide services directly related to hospital operational efficiency. The new business will focus initially on offering services in Europe...
When Medtronic announced that it paid $200 million in cash for chronic disease management firm Cardiocom the medical device giant said the acquisition was indicative of a broader vision for the company's future, but Wall Street analysts are warning that it may also suggest "challenging times ahead" for the device industry.
Medical device giant Medtronic is handing its Pioneer Plus re-entry catheter product line over to Volcano for an undisclosed amount, the companies announced this week. The deal, which Volcano hopes will help it expand its reach in peripheral indications, is expected to close this month and is structured as an "asset purchase."
Another patient injury lawsuit is set to proceed against Medtronic and it's problematic Infuse bone-growth protein after an Arizona district judge ruled that federal preemption doesn't apply in a case accusing the company of off-label marketing, a relatively new tactic that is proving somewhat successful for patients waging battles against medical device makers.
Volcano Corporation Announces Execution Of Agreement To Purchase Pioneer PlusT Re-Entry Catheter Product Line From MedtronicAugust 26, 2013 4:05 pm | by The Associated Press | News | Comments
Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today it has signed an agreement to acquire the Pioneer PlusT diagnostic ultrasound ...
Starting today, medical device giant Medtronic is banned from selling its CoreValve and CoreValve Evolut transcatheter aortic valve implantation systems in Germany, thanks to a court ruling in favor of rival device maker Edwards Lifesciences.
Kent L. Klaudt, lawyer at the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that U.S. District Court Judge G. Murray Snow of the District of Arizona denied in large part Medtronic’s motion to dismiss a personal injury lawsuit brought by Dr. Cristina Ramirez against the company on grounds that the claims are preempted by Federal law.
Investors pushed shares of Medtronic down this morning after the world's largest pure-play medical device company reported mixed results for its fiscal 1st quarter. Fridley, Minn.-based Medtronic posted profits of $953 million, or 93¢ per share, on sales of $4.08 billion for the 3 months ended July 26.
Premier Healthcare Alliance awarded several new contracts for drug-eluting stents, traditional stents and other intervention products to 8 heavy hitters in the cardiology space. Abbott, Boston Scientific, and Medtronic all landed supplier deals for drug-eluting and traditional stents.